#USA #Cambridge #Flagship Pioneering #Department of War #ONTARGET

Flagship Pioneering's Groundbreaking Partnership with the Department of War

In a significant step towards enhancing national security, Flagship Pioneering has been awarded a groundbreaking contract by the Department of War (DoW). This innovative agreement aims to push the boundaries of next-generation medical countermeasure technologies, responding to an ever-evolving landscape of biological threats. Over the next five years, the contract, which could reach up to $47 million, will focus on multiple projects designed to meet the challenges posed by biological and chemical warfare.

A Unique Collaboration

The partnership represents a strategic shift in how the Department of War collaborates with private entities. Instead of following the traditional path of seeking a specific product, this new model allows the DoW to explore a broad spectrum of innovative platform technologies from Flagship’s diverse ecosystem. This ecosystem includes over 40 pioneering biotech companies, which showcase a vast array of capabilities in areas such as translational science, AI/machine learning, and drug development.

Noubar Afeyan, the Founder and CEO of Flagship Pioneering, expressed his enthusiasm about the partnership, stating, "By mobilizing Flagship's unique ecosystem of AI-enabled biotechnologies, we are not only advancing next-generation countermeasures but also building the innovation infrastructure that will define America’s strategic advantage for decades ahead."

The ONTARGET Program

The contract is part of the ONTARGET program (Operationalizing Novel Technologies for Advanced Rapid Generation of Effective Medical Countermeasures) initiated by the DoW’s Joint Science and Technology Office (JSTO). The program aims to enhance military preparedness against adaptive and engineered threats by collaborating with private sector innovators to optimize the performance of medical countermeasures.

Dr. Robert Kristovich, Director of JSTO at the Defense Threat Reduction Agency, emphasized the importance of the agreement. He noted, "Our ultimate goal is to get the best technology into the hands of our warfighters as quickly as possible. The ONTARGET agreement provides a new pathway to do just that, fostering biotechnologies from the private sector."

Initial Research Projects

The funding will initially support innovative projects focusing on medical countermeasures that address specific capabilities deemed vital for national defense. The first two projects involve Flagship-founded companies, Apriori Bio and Prologue Medicines.

Apriori Bio: Developing Resilient Countermeasures

Apriori Bio will leverage its groundbreaking Octavia™ platform, designed to create variant-resilient medical countermeasures. By anticipating potential viral mutations, this platform can speed up the development process, ensuring that medical solutions are effective against a dynamic threat landscape. This approach not only reduces response times but also enhances readiness against biological dangers.

Prologue Medicines: Boosting Immune Response

Prologue Medicines, on the other hand, is set to utilize its DELVE platform to identify viral proteins that can enhance human immune responses. Through advanced AI algorithms, DELVE allows for the discovery of proteins that are evolutionarily optimized, creating adaptable and robust countermeasures that can be deployed in the face of emerging threats.

The Future of Defense Partnerships

The establishment of Flagship Health Security Corporation, a new subsidiary aimed specifically at facilitating government partnerships, further underlines Flagship Pioneering’s commitment to this transformative collaboration. With a history of transforming human health through scientific innovation since its inception in 2000, Flagship Pioneering has consistently been at the forefront of biotech advancement, currently managing over $14 billion in assets and more than 100 scientific ventures.

In conclusion, this partnership between Flagship Pioneering and the Department of War marks a pivotal moment in the realm of medical countermeasures. By harnessing advanced technologies and the innovative capabilities of its ecosystem, Flagship is poised to redefine how national defense approaches biological threats, ultimately contributing to a safer future for all.